Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers
- Improve the long term disease-free survival of patients with rare cancers at high risk
for lethal relapse by using myeloablative chemotherapy with thiotepa, carboplatin, and
topotecan followed by autologous bone marrow or peripheral blood stem cell rescue.
OUTLINE: Autologous bone marrow or peripheral blood stem cells (PBSC) are harvested.
Patients receive high-dose thiotepa IV over 3 hours on days -8 to -6, carboplatin IV over 4
hours on days -5 to -3, and topotecan IV over 30 minutes on days -8 to -4. Autologous bone
marrow or PBSC are reinfused on day 0. Patients receive filgrastim (G-CSF) IV twice daily
beginning on day 1.
Patients are followed for 1 year.
PROJECTED ACCRUAL: Approximately 50 patients will be accrued for this study within 5 years.
Primary Purpose: Treatment
Brian H. Kushner, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|